To evaluate the efficacy of Sarvanga vatha chooranam(Internal), Mukkutu Yennai(External) for the treatment of Santhuvatham(Polyarthritis)

An open clinical study to evaluate the efficacy of Siddha Polyherbal Medicine Sarvanga vatha chooranam(Internal), Mukkutu Yennai(External) and Otradam(External therapy) for the treatment of Santhuvatham(Polyarthritis)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/05/014186

Enrollment

Registered

2018-05-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients Suffering from Polyarthritis

Interventions

Intervention1: Sarvanga vatha chooranam and Mukkutu yennai: Sarvanga vatha chooranam-800-1000mg-oral route twice daily. Otradam(Fomentation)with Mukkutu yennai-30ml-External for 48 days Control Interv

Eligibility

Inclusion criteria

Inclusion criteria: 1. Joints pain : more than 5 joints 2. Swelling 3. Stiffness 4. Restricted movements in affected joint. 5. Willing for admission and study in IPD for 30-40 days or willing to attend OPD

Exclusion criteria

Exclusion criteria: 1. Rheumatoid arthritis 2. Other systemic illness 3. Gout 4. Use of narcotic drugs 5. Tuberculosis

Design outcomes

Primary

Measure	Time frame
The outcome is aimed to reducing the Clinical symptoms and increasing the range of movements.Timepoint: 48 days	—

Secondary

Measure	Time frame
1. To evaluate the effect of otradam in the management of SanthuVatham. 2. To evaluate the Siddha cofactor towards the efficacy of the trial drug SARVANGAVATHA CHOORANAM , MUKKUTU YENNAI and NOCHI ELAI OTRADAM and to evaluate the pharmacological actions. Timepoint: 48 days	—

Countries

India

Contacts

Public ContactGNivetha

Govt.Siddha Medical College Hospital

dr.ahmed63@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026